文献速递产科

39周引产与期待管理基于宫颈检查的成本效果分析

Cost-effectiveness of induction of labor at 39 weeks vs expectant management by cervical examination.
PubMed 文献 · Am J Obstet Gynecol · 2023-01-13

本研究构建两个决策分析模型,比较39周引产与期待管理在宫颈条件不佳和宫颈条件良好未产患者中的成本效果。结果显示,在支付意愿阈值每质量调整生命年10万美元下,宫颈条件不佳者引产具有成本效果,而宫颈条件良好者则无成本效果。

要点

  • 宫颈条件不佳者39周引产每质量调整生命年增量成本为2150美元,宫颈条件良好者为115100美元。
  • 每10万例中,宫颈条件不佳者引产减少3885例剖宫产和58例死产,宫颈条件良好者减少2293例剖宫产和48例死产。
  • 作者认为卫生系统或可优先考虑宫颈条件不佳者进行39周择期引产,这可能与常规实践相反。

核心结论

  • 在支付意愿阈值为每质量调整生命年10万美元下,39周引产对宫颈条件不佳者可能具有成本效果,而对宫颈条件良好者则无成本效果。

研究设计与样本

  • 使用TreeAge软件构建2个决策分析模型,分别模拟宫颈条件不佳和宫颈条件良好的未产患者中39周引产与期待管理的比较,成本和概率估计来自文献。

主要发现

  • 宫颈条件不佳者每质量调整生命年增量成本为2150美元,宫颈条件良好者为115100美元,前者低50倍。
  • 每10万例中,宫颈条件不佳者引产减少3885例剖宫产和58例死产,宫颈条件良好者减少2293例剖宫产和48例死产。
  • 结果对剖宫产可能性、引产成本、阴道或剖宫产分娩成本以及自然临产概率等多个输入参数敏感。
  • 蒙特卡洛分析中,基础案例结果在宫颈条件不佳者的64.1%模拟场景和宫颈条件良好者的55.4%模拟场景中成立。

临床怎么用

  • 作者认为卫生系统或可优先考虑宫颈条件不佳者进行39周择期引产,这可能与常规实践相反。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous analyses have demonstrated the cost effectiveness of elective induction of labor at 39 weeks of gestation for healthy nulliparous people. However, elective induction of labor is resource intensive, and optimal resource allocation requires a thorough understanding of which subgroups of patients will benefit most. OBJECTIVE: This study aimed to determine whether induction of labor at 39 weeks of gestation is more cost-effective in patients with favorable or unfavorable cervical examinations. STUDY DESIGN: We constructed 2 decision analysis models using TreeAge software: one modeling induction of labor at 39 weeks of gestation vs expectant management for a group of nulliparous patients with unfavorable cervical examinations and the other modeling induction of labor at 39 weeks of gestation vs expectant management for a group with favorable cervical examinations. Estimates of cost, probability, and health state utility were derived from the literature. Based on previous literature, we assumed that people with favorable cervical examinations would have a lower baseline rate of cesarean delivery and higher rates of spontaneous labor. RESULTS: In our base case analysis, induction of labor at 39 weeks of gestation was cost-effective for patients with unfavorable cervical examinations, but not for patients with favorable cervical examinations. The incremental cost per quality-adjusted life year was 50-fold lower for people with unfavorable cervical examinations ($2150 vs $115,100). Induction of labor resulted in 3885 fewer cesarean deliveries and 58 fewer stillbirths per 100,000 patients for those with unfavorable examinations, whereas induction of labor resulted in 2293 fewer cesarean deliveries and 48 fewer stillbirths with labor induction for those with favorable cervical examinations. The results were sensitive to multiple inputs, including the likelihood of cesarean delivery, the cost of induction, the cost of vaginal or cesarean delivery, and the probability of spontaneous labor. In Monte Carlo analysis, the base case findings held true for 64.1% of modeled scenarios for patients with unfavorable cervixes and 55.4% of modeled scenarios for patients with favorable cervixes. CONCLUSION: With a willingness-to-pay threshold of $100,000 per quality-adjusted life year, induction of labor at 39 weeks of gestation may be cost-effective for patients with unfavorable cervical examinations, but not for patients with favorable cervical examinations. This result was driven by the likelihood of labor in patients with favorable cervical examinations, and the resultant avoidance of prolonged pregnancy and its complications, including hypertensive disorders of pregnancy and stillbirths. Health systems may wish to prioritize patients with unfavorable cervical examinations for elective induction of labor at 39 weeks of gestation, which may be opposite to common practice.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fitzgerald AC, Kaimal AJ, Little SE, et al. Cost-effectiveness of induction of labor at 39 weeks vs expectant management by cervical examination. Am J Obstet Gynecol. 2023. PMID: 36642340. doi:10.1016/j.ajog.2023.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。